Kazia Therapeutics Limited has announced new findings from an ex vivo study on the effects of paxalisib, its investigational PI3K-mTOR inhibitor, on metastatic burden in Stage IV HER2-positive metastatic breast cancer patients. The study demonstrated that paxalisib monotherapy achieved a complete disruption of circulating tumor cell clusters containing three or more cells. These results highlight paxalisib's potential to address metastatic progression in HER2-positive breast cancer, a subtype that accounts for 15-20% of cases and presents significant clinical challenges. Detailed datasets from this study have been submitted for presentation at an upcoming global oncology meeting in 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN71184) on September 11, 2025, and is solely responsible for the information contained therein.